Jaxteran (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 transcription factor, which up‑regulates antioxidant and cytoprotective genes. This reduces oxidative stress and modulates inflammatory pathways, leading to decreased immune‑mediated damage in the central nervous system and skin, which underlies its efficacy in multiple sclerosis and psoriasis.

The dosage of Jaxteran is determined by the prescribing clinician based on the patient’s condition, tolerability, and clinical response. Physicians typically start with a low dose and may titrate upward, but the exact regimen should always follow the prescriber’s instructions and local labeling.

The pregnancy category for dimethyl fumarate is unknown, and safety data are limited. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Women should discuss family planning and breastfeeding considerations with their healthcare provider.

To request Jaxteran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The primary alternative disease‑modifying therapies for multiple sclerosis include fingolimod and interferon‑beta products. Compared with fingolimod, dimethyl fumarate has a different safety profile, with fewer cardiac monitoring requirements but a higher incidence of flushing and gastrointestinal symptoms. Choice depends on individual patient factors and physician judgment.

Jaxteran should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Jaxteran is taken orally, usually with water. The tablets should be swallowed whole and not crushed, chewed, or broken. Patients are advised to follow the dosing schedule prescribed by their clinician and to maintain consistent timing each day.

The most serious risks include severe lymphopenia, which can predispose to opportunistic infections such as progressive multifocal leukoencephalopathy (PML), as well as rare hepatic injury and severe skin reactions like Stevens‑Johnson syndrome. Regular laboratory monitoring and prompt reporting of new symptoms are essential.

Jaxteran is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any excipients, those with active serious infections, and individuals receiving live vaccines. Caution is also advised for patients with severe hepatic impairment or existing severe lymphopenia.